{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:00:10Z","timestamp":1784973610095,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T00:00:00Z","timestamp":1566000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T00:00:00Z","timestamp":1566000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11011-019-00474-5","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T05:11:07Z","timestamp":1566018667000},"page":"1679-1687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prolactin, flupenthixol decanoate and first episode schizophrenia \u2013 clinical and laboratory correlates"],"prefix":"10.1007","volume":"34","author":[{"given":"Mari","family":"Retief","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonginkosi","family":"Chiliza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lebogang","family":"Phahladira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Emsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Asmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,17]]},"reference":[{"issue":"5","key":"474_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3109\/09540261.2010.515205","volume":"22","author":"Kathryn M. Abel","year":"2010","unstructured":"Abel KM, Drake R, Goldstein JM (2010) Sex differences in schizophrenia. International Review of Psychiatry 22(5):417\u2013428","journal-title":"International Review of Psychiatry"},{"issue":"5","key":"474_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3109\/08039488.2013.839739","volume":"68","author":"Y Albayrak","year":"2014","unstructured":"Albayrak Y, Beyazyuz M, Beyazyuz E, Kuloglu M (2014) Increased serum prolactin levels in drug-naive first-episode male patients with schizophrenia. Nord J Psychiatry 68(5):341\u2013346","journal-title":"Nord J Psychiatry"},{"key":"474_CR3","first-page":"1","volume":"502697","author":"SI Bargiota","year":"2013","unstructured":"Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV (2013) The effects of antipsychotics on prolactin levels and women\u2019s menstruation. Schizophr Res Treat 502697:1\u201310","journal-title":"Schizophr Res Treat"},{"issue":"7","key":"474_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1177\/0269881107078281","volume":"21","author":"C Bushe","year":"2007","unstructured":"Bushe C, Shaw M (2007) Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 21(7):768\u2013773","journal-title":"J Psychopharmacol"},{"issue":"2_suppl","key":"474_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/0269881107088435","volume":"22","author":"C Bushe","year":"2008","unstructured":"Bushe C, Shaw M, Peveler RC (2008) A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 22(2_suppl):46\u201355","journal-title":"J Psychopharmacol"},{"issue":"1","key":"474_CR6","first-page":"14","volume":"14","author":"B Chiliza","year":"2008","unstructured":"Chiliza B, Oosthuizen P, Emsley R (2008) First-episode psychosis: an update. S Afr J Psychiatry 14(1):14\u201319","journal-title":"S Afr J Psychiatry"},{"issue":"3","key":"474_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hup.2469","volume":"30","author":"B Chiliza","year":"2015","unstructured":"Chiliza B, Asmal L, Kilian S, Phahladira L, Emsley R (2015) Rate and predictors of non-response to first-line antipsychotic treatment in first-episode schizophrenia. Hum Psychopharmacol Clin Exp 30(3):173\u2013182","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"1","key":"474_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/eip.12141","volume":"10","author":"B Chiliza","year":"2016","unstructured":"Chiliza B, Ojagbemi A, Esan O, Asmal L, Oosthuizen P, Kidd M, Gureje O, Emsley R (2016) Combining depot antipsychotic with an assertive monitoring programme for treating first-episode schizophrenia in a resource-constrained setting. Early Interv Psychiatry 10(1):54\u201362","journal-title":"Early Interv Psychiatry"},{"issue":"2\u20133","key":"474_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","volume":"76","author":"G Chouinard","year":"2005","unstructured":"Chouinard G, Margolese HC (2005) Manual for the extrapyramidal symptom rating scale (ESRS). Schizophr Res 76(2\u20133):247\u2013265","journal-title":"Schizophr Res"},{"issue":"2_suppl","key":"474_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/0269881107087373","volume":"22","author":"L Citrome","year":"2008","unstructured":"Citrome L (2008) Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 22(2_suppl):90\u201397","journal-title":"J Psychopharmacol"},{"issue":"2017","key":"474_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.schres.2017.01.046","volume":"189","author":"B Crespo-Facorro","year":"2017","unstructured":"Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, P\u00e9rez-Iglesias R, Amado-Se\u00f1aris JA et al (2017) Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: analysis of a randomized open-label 1 year study. Schizophr Res 189(2017):134\u2013141","journal-title":"Schizophr Res"},{"issue":"1","key":"474_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/pnp.56","volume":"12","author":"A Crockett","year":"2008","unstructured":"Crockett A, Goldstein M (2008) Treatment of outpatients with schizophrenia in a depot clinic. Prog Neurol Psychiatry 12(1):18\u201323","journal-title":"Prog Neurol Psychiatry"},{"key":"474_CR13","doi-asserted-by":"crossref","unstructured":"da Silva TL, Ravindran AV (2015) Contribution of sex hormones to gender differences in schizophrenia: a review. Asian J Psychiatr 18:2\u201314","DOI":"10.1016\/j.ajp.2015.07.016"},{"issue":"4","key":"474_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1600-0447.2006.00897.x","volume":"115","author":"J Eberhard","year":"2007","unstructured":"Eberhard J, Lindstr\u00f6m E, Holstad M, Levander S (2007) Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr Scand 115(4):268\u2013276","journal-title":"Acta Psychiatr Scand"},{"key":"474_CR15","unstructured":"First M, Spitzer RL, Gibbon ML, Williams J (2002) Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition."},{"issue":"20","key":"474_CR16","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia. Drugs 64(20):2291\u20132314","journal-title":"Drugs"},{"issue":"1","key":"474_CR17","first-page":"45","volume":"47","author":"ICH harmonized tripartite guideline","year":"2001","unstructured":"ICH harmonized tripartite guideline (2001) Guideline for good clinical practice. J Postgrad Med 47(1):45\u201350","journal-title":"J Postgrad Med"},{"issue":"10","key":"474_CR18","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3109\/00048674.2011.589044","volume":"45","author":"WJ Inder","year":"2011","unstructured":"Inder WJ, Castle D (2011) Antipsychotic-induced hyperprolactinaemia. Aust N Z J Psychiatry 45(10):830\u2013837","journal-title":"Aust N Z J Psychiatry"},{"issue":"9618","key":"474_CR19","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085\u20131097","journal-title":"Lancet"},{"issue":"1","key":"474_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0165-1781(88)90038-8","volume":"23","author":"SR Kay","year":"1988","unstructured":"Kay SR, Opler LA, Lindenmayer JP (1988) Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23(1):99\u2013110","journal-title":"Psychiatry Res"},{"issue":"401","key":"474_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.0065-1591.2000.0ap25.x","volume":"101","author":"Dr. Alice Leung M.D.","year":"2000","unstructured":"Leung A, Chue P (2000) Sex differences in schizophrenia: a review of the literature. Acta Psychiatria Scandinavica 101(401):3\u201338","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"474_CR22","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.2174\/1568026616666160608084834","volume":"646","author":"P Li","year":"2016","unstructured":"Li P, Snyder GL, Vanover KE (2016) Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem 646:3385\u20133403","journal-title":"Curr Top Med Chem"},{"issue":"6","key":"474_CR23","first-page":"1047","volume":"3","author":"I Marrag","year":"2015","unstructured":"Marrag I, Hajji K, Braham MY, Dhifallah M, Nasr M (2015) Antipsychotics and hyperprolactinemia: prevalence and risk factors. Ann Psychiatry Ment Health 3(6):1047","journal-title":"Ann Psychiatry Ment Health"},{"issue":"4","key":"474_CR24","first-page":"483","volume":"14","author":"VP Matei","year":"2019","unstructured":"Matei VP, Purnichi T, Mihailescu A, Grigoras R (2019) Prolactin level in patients with First episode schizophrenia treated for one year with atypical antipsychotics. Acta Endocrinol 14(4):483\u2013490","journal-title":"Acta Endocrinol"},{"issue":"7","key":"474_CR25","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","volume":"164","author":"JP McEvoy","year":"2007","unstructured":"McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatr 164(7):1050\u20131060","journal-title":"Am J Psychiatr"},{"issue":"9","key":"474_CR26","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0024-3205(02)01775-7","volume":"71","author":"AM Meaney","year":"2002","unstructured":"Meaney AM, O'Keane V (2002) Prolactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci 71(9):979\u2013992","journal-title":"Life Sci"},{"issue":"4","key":"474_CR27","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/j.1600-0447.2006.00982.x","volume":"115","author":"HA Nasrallah","year":"2007","unstructured":"Nasrallah HA (2007) The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 115(4):260\u2013267","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"474_CR28","first-page":"421","volume":"28","author":"J Peuskens","year":"2014","unstructured":"Peuskens J, Pani L, Detraux J, De Hert M (2014) The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 28(5):421\u2013453","journal-title":"CNS Drugs"},{"issue":"3","key":"474_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1093\/schbul\/sbi032","volume":"31","author":"DG Robinson","year":"2005","unstructured":"Robinson DG, Woerner MG, Delman HM, Kane JM (2005) Pharmacological treatments for first-episode schizophrenia. Schizophr Bull 31(3):705\u2013722","journal-title":"Schizophr Bull"},{"key":"474_CR30","doi-asserted-by":"crossref","unstructured":"Sykes DA, Moore H, Stott L, Holliday N, Javitch JA, Lane JR et al (2017) Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun 763(8):1\u201311","DOI":"10.1038\/s41467-017-00716-z"},{"issue":"6","key":"474_CR31","doi-asserted-by":"publisher","first-page":"e00364","DOI":"10.1002\/prp2.364","volume":"5","author":"Amit Taneja","year":"2017","unstructured":"Taneja A, Vermeulen A, Huntjens DRH, Danhof M, De Lange ECM, Proost JH (2017) Modeling of prolactin response following dopamine D2 receptor antagonists in rats : can it be translated to clinical dosing ? Pharmacol Res Perspect 5(6):1\u201315","journal-title":"Pharmacology Research & Perspectives"},{"issue":"4","key":"474_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/alcalc\/36.4.329","volume":"36","author":"GA Wiesbeck","year":"2001","unstructured":"Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J (2001) Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol 36(4):329\u2013334","journal-title":"Alcohol Alcohol"},{"issue":"3","key":"474_CR33","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0165-1781(02)00022-7","volume":"109","author":"XY Zhang","year":"2002","unstructured":"Zhang XY, Zhou DF, Yuan CL, Zhang PY, Wu GY, Shen YC (2002) Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 109(3):297\u2013302","journal-title":"Psychiatry Res"},{"issue":"6","key":"474_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1017\/S1461145712001277","volume":"16","author":"JP Zhang","year":"2013","unstructured":"Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 16(6):1205\u20131218","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-019-00474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-019-00474-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-019-00474-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T23:43:28Z","timestamp":1597535008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-019-00474-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,17]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["474"],"URL":"https:\/\/doi.org\/10.1007\/s11011-019-00474-5","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,17]]},"assertion":[{"value":"22 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}